• 1
    Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26: 166174.
  • 2
    McHugh CG, Riley LW. Risk factors and costs associated with methicillin-resistant Staphylococcus aureus bloodstream infections. Infect Control Hosp Epidemiol 2004; 25: 425430.
  • 3
    Gould IM, Reilly J, Bunyan D, Walker A. Costs of healthcare-associated methicillin-resistant Staphylococcus aureus and its control. Clin Microbiol Infect 2010; 16: 17211728.
  • 4
    Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36: 5359.
  • 5
    Nulens E, Broex E, Ament A et al. Cost of the methicillin-resistant Staphylococcus aureus search and destroy policy in a Dutch University Hospital. J Hosp Infect 2008; 68: 301307.
  • 6
    Kock R, Becker K, Cookson B et al. Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill 2010; 15: 19688.
  • 7
    Goetghebeur M, Landry PA, Han D, Vicente C. Methicillin-resistant Staphylococcus aureus: a public health issue with economic consequences. Can J Infect Dis Med Microbiol 2007; 18: 2734.
  • 8
  • 9
    Johnson AP, Davies J, Guy R et al. Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 years. J Antimicrob Chemother 2012; 67: 802809.
  • 10
    Ritchie K, Bradbury I, Craig J et al. The clinical and cost effectiveness of screening for meticillin-resistant Staphylococcus aureus (MRSA). 2007; 10; NHS Quality Improvement Scotland, HTA Report 9.
  • 11
    Bootsma MC, Diekmann O, Bonten MJ. Controlling methicillin-resistant Staphylococcus aureus: quantifying the effects of interventions and rapid diagnostic testing. Proc Natl Acad Sci USA 2006; 103: 56205625.
  • 12
    Ofman JJ, Sullivan SD, Neumann PJ et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm 2003; 9: 5361.
  • 13
    Wernitz MH, Keck S, Swidsinski S, Schulz S, Veit SK. Cost analysis of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers in the context of diagnosis related groups (DRG) payment. Clin Microbiol Infect 2005; 11: 466471.
  • 14
    Simoens S, Ophals E, Schuermans A. Search and destroy policy for methicillin-resistant Staphylococcus aureus: cost–benefit analysis. J Adv Nurs 2009; 65: 18531859.
  • 15
    van Rijen MM, Kluytmans JA. Costs and benefits of the MRSA Search and Destroy policy in a Dutch hospital. Eur J Clin Microbiol Infect Dis 2009; 28: 12451252.
  • 16
    Vriens M, Blok H, Fluit A, Troelstra A, Van Der Werken C, Verhoef J. Costs associated with a strict policy to eradicate methicillin-resistant Staphylococcus aureus in a Dutch University Medical Center: a 10-year survey. Eur J Clin Microbiol Infect Dis 2002; 21: 782786.
  • 17
    Rao N, Jacobs S, Joyce L. Cost-effective eradication of an outbreak of methicillin-resistant Staphylococcus aureus in a community teaching hospital. Infect Control Hosp Epidemiol 1988; 9: 255260.
  • 18
    Nixon M, Jackson B, Varghese P, Jenkins D, Taylor G. Methicillin-resistant Staphylococcus aureus on orthopaedic wards: incidence, spread, mortality, cost and control. J Bone Joint Surg Br 2006; 88: 812817.
  • 19
    West TE, Guerry C, Hiott M, Morrow N, Ward K, Salgado CD. Effect of targeted surveillance for control of methicillin-resistant Staphylococcus aureus in a community hospital system. Infect Control Hosp Epidemiol 2006; 27: 233238.
  • 20
    Clancy M, Graepler A, Wilson M, Douglas I, Johnson J, Price CS. Active screening in high-risk units is an effective and cost-avoidant method to reduce the rate of methicillin-resistant Staphylococcus aureus infection in the hospital. Infect Control Hosp Epidemiol 2006; 27: 10091017.
  • 21
    Knausz M, Kaproncai G, Rozgonyi F. Cost/benefit calculations of methicillin-resistant Staphylococcus aureus screening methods and their practical importance. Orv Hetil 2010; 151: 893898.
  • 22
    Karchmer TB, Durbin LJ, Simonton BM, Farr BM. Cost-effectiveness of active surveillance cultures and contact/droplet precautions for control of methicillin-resistant Staphylococcus aureus. J Hosp Infect 2002; 51: 126132.
  • 23
    Gavalda L, Masuet C, Beltran J et al. Comparative cost of selective screening to prevent transmission of methicillin-resistant Staphylococcus aureus (MRSA), compared with the attributable costs of MRSA infection. Infect Control Hosp Epidemiol 2006; 27: 12641266.
  • 24
    Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C. Control of endemic methicillin-resistant Staphylococcus aureus: a cost–benefit analysis in an intensive care unit. JAMA 1999; 282: 17451751.
  • 25
    Keshtgar MR, Khalili A, Coen PG et al. Impact of rapid molecular screening for methicillin-resistant Staphylococcus aureus in surgical wards. Br J Surg 2008; 95: 381386.
  • 26
    Jernigan JA, Clemence MA, Stott GA et al. Control of methicillin-resistant Staphylococcus aureus at a university hospital: one decade later. Infect Control Hosp Epidemiol 1995; 16: 686696.
  • 27
    Leonhardt KK, Yakusheva O, Phelan D et al. Clinical effectiveness and cost benefit of universal versus targeted methicillin-resistant Staphylococcus aureus screening upon admission in hospitals. Infect Control Hosp Epidemiol 2011; 32: 797803.
  • 28
    Nyman JA, Lees CH, Bockstedt LA et al. Cost of screening intensive care unit patients for methicillin-resistant Staphylococcus aureus in hospitals. Am J Infect Control 2011; 39: 2734.
  • 29
    Bjorholt I, Haglind E. Cost-savings achieved by eradication of epidemic methicillin-resistant Staphylococcus aureus (EMRSA)-16 from a large teaching hospital. Eur J Clin Microbiol Infect Dis 2004; 23: 688695.
  • 30
    Herr CE, Heckrodt TH, Hofmann FA, Schnettler R, Eikmann TF. Additional costs for preventing the spread of methicillin-resistant Staphylococcus aureus and a strategy for reducing these costs on a surgical ward. Infect Control Hosp Epidemiol 2003; 24: 673678.
  • 31
    Papia G, Louie M, Tralla A, Johnson C, Collins V, Simor AE. Screening high-risk patients for methicillin-resistant Staphylococcus aureus on admission to the hospital: is it cost effective? Infect Control Hosp Epidemiol 1999; 20: 473477.
  • 32
    Tavolacci MP, Merle V, Dupuis M et al. Choice of a strategy for screening for methicillin-resistant Staphylococcus aureus on admission to rehabilitation units. Presse Med 2004; 33: 15751578.
  • 33
    Forward KR. The value of multiple surveillance cultures for methicillin-resistant Staphylococcus aureus. Am J Infect Control 2010; 38: 596599.
  • 34
    Uckay I, Sax H, Iten A et al. Effect of screening for methicillin-resistant Staphylococcus aureus carriage by polymerase chain reaction on the duration of unnecessary preemptive contact isolation. Infect Control Hosp Epidemiol 2008; 29: 10771079.
  • 35
    Wassenberg MW, Kluytmans JA, Box AT et al. Rapid screening of methicillin-resistant Staphylococcus aureus using PCR and chromogenic agar: a prospective study to evaluate costs and effects. Clin Microbiol Infect 2010; 16: 17541761.
  • 36
    Conterno LO, Shymanski J, Ramotar K et al. Real-time polymerase chain reaction detection of methicillin-resistant Staphylococcus aureus: impact on nosocomial transmission and costs. Infect Control Hosp Epidemiol 2007; 28: 11341141.
  • 37
    Could IM, MacKenzie FM, MacLennan G, Pacitti D, Watson EJ, Noble DW. Topical antimicrobials in combination with admission screening and barrier precautions to control endemic methicillin-resistant Staphylococcus aureus in an Intensive Care Unit. Int J Antimicrob Agents 2007; 29: 536543.
  • 38
    Walsh TJ, Vlahov D, Hansen SL et al. Prospective microbiologic surveillance in control of nosocomial methicillin-resistant Staphylococcus aureus. Infect Control 1987; 8: 714.
  • 39
    Morgan DJ, Day HR, Furuno JP et al. Improving efficiency in active surveillance for methicillin-resistant Staphylococcus aureus or vancomycin-resistant Enterococcus at hospital admission. Infect Control Hosp Epidemiol 2010; 31: 12301235.
  • 40
    Spence MR, Dammel T, Courser S. Contact precautions for methicillin-resistant Staphylococcus aureus colonization: costly and unnecessary? Am J Infect Control 2012; 40: 535538.
  • 41
    Garcia R, Vonderheid S, McFarlin B, Djonlich M, Jang C, Maghirang J. Cost and health outcomes associated with mandatory MRSA screening in a special care nursery. Adv Neonatal Care 2011; 11: 200207.
  • 42
    Buhlmann M, Bogli-Stuber K, Droz S, Muhlemann K. Rapid screening for carriage of methicillin-resistant Staphylococcus aureus by PCR and associated costs. J Clin Microbiol 2008; 46: 21512154.
  • 43
    Creamer E, Galvin S, Dolan A et al. Evaluation of screening risk and nonrisk patients for methicillin-resistant Staphylococcus aureus on admission in an acute care hospital. Am J Infect Control 2012; 40: 411415.
  • 44
    Bantar C, Sartori B, Vesco E et al. A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis 2003; 37: 180186.
  • 45
    Frank MO, Batteiger BE, Sorensen SJ et al. Decrease in expenditures and selected nosocomial infections following implementation of an antimicrobial-prescribing improvement program. Clin Perform Qual Health Care 1997; 5: 180188.
  • 46
    Geissler A, Gerbeaux P, Granier I, Blanc P, Facon K, Durand-Gasselin J. Rational use of antibiotics in the intensive care unit: impact on microbial resistance and costs. Intensive Care Med 2003; 29: 4954.
  • 47
    Souweine B, Traore O, Aublet-Cuvelier B et al. Role of infection control measures in limiting morbidity associated with multi-resistant organisms in critically ill patients. J Hosp Infect 2000; 45: 107116.
  • 48
    Bishara J, Goldberg E, Leibovici L et al. Healthcare-associated vs. hospital-acquired Staphylococcus aureus bacteremia. Int J Infect Dis 2012; 16: e457e463.
  • 49
    Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008; 46: 349356.
  • 50
    Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13: 437452.
  • 51
    Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20: 332342.
  • 52
    Weinstein MC. How much are Americans willing to pay for a quality-adjusted life year? Med Care 2008; 46: 343345.
  • 53
    Loveday HP, Pellowe CM, Jones SR, Pratt RJ. A systematic review of the evidence for interventions for the prevention and control of methicillin-resistant Staphylococcus aureus (1996–2004): report to the Joint MRSA Working Party (Subgroup A). J Hosp Infect 2006; 63 (suppl 1): S45S70.
  • 54
    Tacconelli E, De Angelis G, de Waure C, Cataldo MA, La Torre G, Cauda R. Rapid screening tests for methicillin-resistant Staphylococcus aureus at hospital admission: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 546554.
  • 55
    Cooper BS, Stone SP, Kibbler CC et al. Isolation measures in the hospital management of methicillin resistant Staphylococcus aureus (MRSA): systematic review of the literature. BMJ 2004; 329: 533.
  • 56
    Korczak D, Schoffmann C. Medical and health economic evaluation of prevention- and control measures related to MRSA infections or -colonisations at hospitals. GMS Health Technol Assess 2010; 6: Doc04.
  • 57
    Stone SP, Cooper BS, Kibbler CC et al. The ORION statement: guidelines for transparent reporting of outbreak reports and intervention studies of nosocomial infection. J Antimicrob Chemother 2007; 59: 833840.